Literature DB >> 23584985

Novel risk factors for cardiovascular disease in rheumatoid arthritis.

Jenny Amaya-Amaya1, Juan Camilo Sarmiento-Monroy, Ruben-Dario Mantilla, Ricardo Pineda-Tamayo, Adriana Rojas-Villarraga, Juan-Manuel Anaya.   

Abstract

Since cardiovascular disease (CVD) is the most common cause of mortality in patients with rheumatoid arthritis (RA), we aimed to determine factors associated with such a complication in a large series of Colombian patients. This was a cross-sectional analytical study in which 800 consecutive Colombian patients with RA were assessed for variables associated with CVD. Furthermore, a systematic literature review was performed to address the state of the art about non-traditional risk factors for CVD in RA. The preferred reporting items for systematic reviews and meta-analyses guidelines were followed in data extraction, analysis, and reporting of articles selected. Hypercholesterolemia, type 2 diabetes mellitus, abnormal body mass index, abdominal obesity, and current smoking were all traditional risk factors significantly associated with CVD in Colombians. As non-traditional risk factors, familial autoimmunity, more than 10 years of duration of the disease, patients working on household duties, use of systemic steroids, and low education level were associated with CVD in the studied population. Out of a total of 9,812 articles identified in PubMed and Scopus databases, 140 fulfilled the eligibility criteria and were included. Through this systematic review, several factors and outcomes related to CVD were confirmed and identified. These were categorized into genetics, RA-related, and others. Traditional risk factors do not completely explain the high rates of CVD in patients with RA; thus, novel risk factors related to autoimmunity are now recognized predicting the presence of CVD as strong as traditional risk factors. Our results may assist health professionals and policymakers in making decisions about CVD in patients with RA.

Entities:  

Mesh:

Year:  2013        PMID: 23584985     DOI: 10.1007/s12026-013-8398-7

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  180 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

2.  [Relationship of silent myocardial ischiemia with the course of rheumatoid arthritis and hyperhomocysteinemia].

Authors:  O Iu Galiutina; O V Bychak
Journal:  Lik Sprava       Date:  2011 Jan-Mar

3.  Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA.

Authors:  A Nakajima; E Inoue; E Tanaka; G Singh; E Sato; D Hoshi; K Shidara; M Hara; S Momohara; A Taniguchi; N Kamatani; H Yamanaka
Journal:  Scand J Rheumatol       Date:  2010       Impact factor: 3.641

4.  The kaleidoscope of autoimmunity: multiple autoimmune syndromes and familial autoimmunity.

Authors:  Juan-Manuel Anaya; Rodrigo Corena; John Castiblanco; Adriana Rojas-Villarraga; Yehuda Shoenfeld
Journal:  Expert Rev Clin Immunol       Date:  2007-07       Impact factor: 4.473

5.  Cystatin C, renal function, and atherosclerosis in rheumatoid arthritis.

Authors:  Ratchaya Lertnawapan; Aihua Bian; Young Hee Rho; Vivian K Kawai; Paolo Raggi; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein
Journal:  J Rheumatol       Date:  2011-08-15       Impact factor: 4.666

6.  High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.

Authors:  I D del Rincón; K Williams; M P Stern; G L Freeman; A Escalante
Journal:  Arthritis Rheum       Date:  2001-12

7.  Rheumatoid arthritis, periodontal disease and coronary artery disease.

Authors:  S Abou-Raya; A Abou-Raya; A Naim; H Abuelkheir
Journal:  Clin Rheumatol       Date:  2007-08-29       Impact factor: 2.980

8.  Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis.

Authors:  Yu Asanuma; Cecilia P Chung; Annette Oeser; Joseph F Solus; Ingrid Avalos; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; Tuulikki Sokka; Theodore Pincus; C Michael Stein
Journal:  Atherosclerosis       Date:  2007-06-14       Impact factor: 5.162

9.  Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis.

Authors:  Patrick H Dessein; Gavin R Norton; Angela J Woodiwiss; Barry I Joffe; Fred Wolfe
Journal:  J Rheumatol       Date:  2007-04-15       Impact factor: 4.666

10.  Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Ann-Charlotte Elkan; Niclas Håkansson; Johan Frostegård; Tommy Cederholm; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2009-03-10       Impact factor: 5.156

View more
  15 in total

Review 1.  Microparticles and autophagy: a new frontier in the understanding of atherosclerosis in rheumatoid arthritis.

Authors:  C Barbati; M Vomero; T Colasanti; F Ceccarelli; M Marcosano; F Miranda; L Novelli; A Pecani; Carlo Perricone; F R Spinelli; S Truglia; F Conti; G Valesini; C Alessandri
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

Review 2.  Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps.

Authors:  Thomas Zegkos; George Kitas; Theodoros Dimitroulas
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-04-30       Impact factor: 5.346

3.  Metabolic abnormalities in rheumatoid arthritis patients with comorbid diabetes mellitus.

Authors:  Xing Zhen Liu; Ying Gao; Jie Fan; Xia Xu; Ju Zhang; Jie Gao; Wei Wan; Dong Bao Zhao
Journal:  Clin Rheumatol       Date:  2017-09-24       Impact factor: 2.980

4.  Myeloperoxidase as an important predictor of cardiovascular risk in individuals with rheumatoid arthritis.

Authors:  Elisangela Gueiber Montes; Fabiana Postiglioni Mansani; Alceu de Oliveira Toledo Júnior; Marcelo Derbli Schafranski; Bruno Queiroz Zardo; Fábio André Dos Santos; Sabrina Grassiolli; Lorena de Freitas Calixto; Rômulo Lopes da Costa; Felício de Freitas Netto; José Carlos Rebuglio Vellosa
Journal:  Inflammopharmacology       Date:  2021-11-26       Impact factor: 4.473

5.  Hyperlipidemia in rheumatoid arthritis patients in Saudi Arabia. Correlation with C-reactive protein levels and disease activity.

Authors:  Suzan M Attar
Journal:  Saudi Med J       Date:  2015-06       Impact factor: 1.484

6.  GDF15(MIC1) H6D Polymorphism Does Not Influence Cardiovascular Disease in a Latin American Population with Rheumatoid Arthritis.

Authors:  Jenny Amaya-Amaya; Adriana Rojas-Villarraga; Nicolas Molano-Gonzalez; Laura Montoya-Sánchez; Swapan K Nath; Juan-Manuel Anaya
Journal:  J Immunol Res       Date:  2015-05-18       Impact factor: 4.818

7.  The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.

Authors:  Chiara Baldini; Francesca Romana Moriconi; Sara Galimberti; Peter Libby; Raffaele De Caterina
Journal:  Eur Heart J       Date:  2021-11-07       Impact factor: 35.855

8.  Classical cardiovascular disease risk factors associate with vascular function and morphology in rheumatoid arthritis: a six-year prospective study.

Authors:  Aamer Sandoo; Neil Chanchlani; James Hodson; Jacqueline P Smith; Karen M Douglas; George D Kitas
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

9.  Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Julián Caro-Moreno; Nicolás Molano-González; Rubén D Mantilla; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Autoimmune Dis       Date:  2013-11-03

Review 10.  Cardiovascular involvement in autoimmune diseases.

Authors:  Jenny Amaya-Amaya; Laura Montoya-Sánchez; Adriana Rojas-Villarraga
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.